Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKONEX 2295001 trials

NovMetaPharma Co., Ltd.

Official website

KONEX-listed biotech developing NovDB2, NovDKD, and NovFSHD drug pipelines for metabolic disease and fibrosis.

As of 2026-10-10, NovMetaPharma Co., Ltd. has 21 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2010 and listed on KONEX in 2015, NovMetaPharma develops drugs for metabolic, inflammatory, and fibrotic diseases. Its pipeline centers on diabetes drug NovDB2, kidney drug NovDKD, and FSHD drug NovFSHD, plus health food sales and C01 skin booster marketing. It targets Phase 2 before out-licensing, with Phase 2b done for NovDB2/NovOB and IRB approval for NovDKD's Phase 2 trial.

Products & technology

  • 신약 관련 원료
  • 건강기능식품
  • C01 기반 스킨부스터

Clinical trials

data.go.kr

1 MFDS clinical trial authorisations · 2023 (Phase 2 1)

  • Phase 2Cyclo-Z2023-03-14

    14 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

NovDB2 · 2형 당뇨병 · 미국 임상 2b상 완료 · Novel-mechanism insulin resistance drug; follow-up trial integrated into the NovDKD Phase 2 program

NovDKD · 당뇨병콩팥병 · 국내 임상 2상(2024년 2분기 IRB 승인 완료) · Novel-substance kidney disease drug; safety verified through FDA Phase 2b in type 2 diabetes patients

NovFSHD / NovFSHD2 · FSHD(안면견갑상완근위축증) · 2026년 중 임상 2상 진입 예정(일반인 대상 1상 완료) · Efficacy verified in animal models by a major North American FSHD institution

NovOB-M · GLP1 비만치료제 관련 근감소증 · 1상 완료(일반인 대상) · Studied as a co-administered therapy with GLP-1 obesity drugs to address muscle loss/function decline

NovFS-IP · 특발성 폐섬유증 · 1상 완료(일반인 대상) · FDA orphan drug designation granted; safety verified through FDA Phase 2b in type 2 diabetes patients

NovSR · 근감소증(노화 관련) · 1상 진입 예정(IND 안전성 자료 확보)

NovDMD · 듀센근이영양증 · 1상 예정(IND 안전성 자료 완료) · Related research published in Advanced Science (2024)

NovAP · 급성췌장염 · 전임상 · Novel-mechanism drug; seeking a partner for out-licensing/co-development

NovLC · 간암 · 전임상 · Shown potential to overcome sorafenib resistance; seeking an out-licensing partner

Publications

PubMed · affiliation-matched
Show 11 more publications

Patents

KIPRIS · applicant-matched
Show 141 more patents

AI reads

MAA server logs · IP-verified
52
Times AI engines pulled NovMetaPharma Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

51
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 0
Last 7 days
47
live 1
Last 30 days
52
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot46
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1
  • PerplexityPerplexityBot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for NovMetaPharma Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition